1. Home
  2. COGT vs LUNR Comparison

COGT vs LUNR Comparison

Compare COGT & LUNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COGT
  • LUNR
  • Stock Information
  • Founded
  • COGT 2014
  • LUNR 2013
  • Country
  • COGT United States
  • LUNR United States
  • Employees
  • COGT N/A
  • LUNR N/A
  • Industry
  • COGT Biotechnology: Pharmaceutical Preparations
  • LUNR Industrial Machinery/Components
  • Sector
  • COGT Health Care
  • LUNR Industrials
  • Exchange
  • COGT Nasdaq
  • LUNR Nasdaq
  • Market Cap
  • COGT 1.1B
  • LUNR 1.1B
  • IPO Year
  • COGT 2018
  • LUNR N/A
  • Fundamental
  • Price
  • COGT $12.36
  • LUNR $9.28
  • Analyst Decision
  • COGT Strong Buy
  • LUNR Buy
  • Analyst Count
  • COGT 11
  • LUNR 7
  • Target Price
  • COGT $21.20
  • LUNR $13.71
  • AVG Volume (30 Days)
  • COGT 1.5M
  • LUNR 5.1M
  • Earning Date
  • COGT 11-11-2025
  • LUNR 11-13-2025
  • Dividend Yield
  • COGT N/A
  • LUNR N/A
  • EPS Growth
  • COGT N/A
  • LUNR N/A
  • EPS
  • COGT N/A
  • LUNR N/A
  • Revenue
  • COGT N/A
  • LUNR $225,977,000.00
  • Revenue This Year
  • COGT N/A
  • LUNR $13.03
  • Revenue Next Year
  • COGT N/A
  • LUNR $45.16
  • P/E Ratio
  • COGT N/A
  • LUNR N/A
  • Revenue Growth
  • COGT N/A
  • LUNR 42.86
  • 52 Week Low
  • COGT $3.72
  • LUNR $5.34
  • 52 Week High
  • COGT $13.50
  • LUNR $24.95
  • Technical
  • Relative Strength Index (RSI)
  • COGT 52.66
  • LUNR 52.53
  • Support Level
  • COGT $12.28
  • LUNR $8.73
  • Resistance Level
  • COGT $13.13
  • LUNR $9.42
  • Average True Range (ATR)
  • COGT 0.52
  • LUNR 0.40
  • MACD
  • COGT -0.08
  • LUNR 0.17
  • Stochastic Oscillator
  • COGT 30.06
  • LUNR 77.30

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

About LUNR Intuitive Machines Inc.

Intuitive Machines Inc is a space exploration, infrastructure, and services company. It is a diversified space company focused on space exploration. It supplies space products and services to support sustained robotic and human exploration to the Moon, Mars, and beyond. Its products and services are offered through its four business units: Lunar Access Services, Orbital Services, Lunar Data Services, and Space Products and Infrastructure. The Company operates in one operating segment and one reportable segment underpinned by three core pillars (delivery services, data transmission services, and infrastructure as a service) that have similar capabilities, customers, and economic characteristics. Revenue is from contracts with customers of orbital and lunar access services.

Share on Social Networks: